Corteva (NYSE:CTVA) Price Target Raised to $90.00

Corteva (NYSE:CTVA) had its price objective raised by stock analysts at UBS Group from $88.00 to $90.00 in a research note issued to investors on Thursday,Benzinga reports. The firm presently has a “neutral” rating on the stock. UBS Group’s target price suggests a potential upside of 13.73% from the company’s previous close.

CTVA has been the topic of several other reports. Deutsche Bank Aktiengesellschaft lifted their price target on Corteva from $85.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, February 5th. Mizuho lifted their price target on Corteva from $82.00 to $94.00 and gave the company an “outperform” rating in a research report on Wednesday, April 15th. Oppenheimer lifted their price target on Corteva from $86.00 to $89.00 and gave the company an “outperform” rating in a research report on Wednesday, April 22nd. Bank of America lifted their price target on Corteva from $80.00 to $82.00 and gave the company a “buy” rating in a research report on Thursday, January 8th. Finally, CICC Research lifted their price target on Corteva from $70.00 to $80.00 and gave the company an “outperform” rating in a research report on Wednesday, February 11th. Fourteen investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $86.95.

Corteva Stock Performance

CTVA traded down $2.64 during trading hours on Thursday, hitting $79.14. The company’s stock had a trading volume of 6,274,985 shares, compared to its average volume of 4,024,688. Corteva has a fifty-two week low of $60.53 and a fifty-two week high of $85.63. The company has a current ratio of 1.43, a quick ratio of 0.96 and a debt-to-equity ratio of 0.07. The firm has a market capitalization of $53.13 billion, a PE ratio of 46.55, a PEG ratio of 2.88 and a beta of 0.59. The company has a 50-day simple moving average of $80.66 and a 200 day simple moving average of $72.48.

Corteva (NYSE:CTVA) last posted its earnings results on Tuesday, May 5th. The company reported $1.50 EPS for the quarter, beating the consensus estimate of $1.18 by $0.32. Corteva had a return on equity of 9.88% and a net margin of 6.50%.The firm had revenue of $4.91 billion for the quarter, compared to analysts’ expectations of $4.64 billion. During the same period last year, the firm earned $1.13 EPS. The firm’s revenue was up 11.0% compared to the same quarter last year. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. As a group, sell-side analysts expect that Corteva will post 3.62 EPS for the current year.

Insider Activity at Corteva

In other news, insider Brian Titus sold 8,311 shares of the firm’s stock in a transaction on Friday, February 20th. The stock was sold at an average price of $76.55, for a total value of $636,207.05. Following the completion of the sale, the insider owned 8,090 shares of the company’s stock, valued at $619,289.50. This trade represents a 50.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 0.15% of the stock is currently owned by company insiders.

Institutional Trading of Corteva

Several hedge funds and other institutional investors have recently modified their holdings of CTVA. Brighton Jones LLC boosted its position in shares of Corteva by 307.2% in the fourth quarter. Brighton Jones LLC now owns 15,588 shares of the company’s stock worth $888,000 after buying an additional 11,760 shares during the period. Woodline Partners LP boosted its position in shares of Corteva by 40.3% in the first quarter. Woodline Partners LP now owns 57,919 shares of the company’s stock worth $3,645,000 after buying an additional 16,644 shares during the period. EverSource Wealth Advisors LLC boosted its position in Corteva by 62.1% during the second quarter. EverSource Wealth Advisors LLC now owns 2,559 shares of the company’s stock valued at $191,000 after purchasing an additional 980 shares during the last quarter. Cresset Asset Management LLC boosted its position in Corteva by 2.6% during the second quarter. Cresset Asset Management LLC now owns 7,063 shares of the company’s stock valued at $526,000 after purchasing an additional 181 shares during the last quarter. Finally, Jump Financial LLC acquired a new stake in Corteva during the second quarter valued at $1,464,000. Institutional investors and hedge funds own 81.54% of the company’s stock.

Key Headlines Impacting Corteva

Here are the key news stories impacting Corteva this week:

• Positive Sentiment: Corteva reported a stronger?than?expected Q1 (EPS and revenue beats), reaffirmed its 2026 outlook and said it remains on track for the planned 4Q?2026 separation — fundamental results that support upside. Corteva Agriscience: Corteva Delivers Strong 1Q 2026, Reaffirms 2026 Outlook, On-Track for 4Q 2026 Separation
• Positive Sentiment: Jefferies raised its price target to $97, implying sizable upside versus current levels — a bullish analyst signal that can support the stock. Jefferies adjusts price target on Corteva to $97 from $95
• Neutral Sentiment: Management (CEO Chuck Magro and CFO David Johnson) will present at the BMO Global Farm to Market conference on May 14 — an event where management can reiterate guidance and answer analyst questions, but not an immediate catalyst. Corteva to Participate in BMO Global Farm to Market Conference
• Neutral Sentiment: Transcripts and the earnings presentation are now available for deeper review — useful for investors who want detail on margins, regional demand and guidance drivers. Corteva, Inc. (CTVA) Q1 2026 Earnings Call Transcript
• Negative Sentiment: BNP Paribas Exane lifted its target only to $77, which sits below current market levels and signals some analyst caution about upside from here — a factor contributing to downward pressure. BNP Paribas adjusts price target on Corteva to $77 from $74

Corteva Company Profile

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid?2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.